Dimethylarginine Dimethylaminohydrolase Prevents Progression of Renal Dysfunction by Inhibiting Loss of Peritubular Capillaries and Tubulointerstitial Fibrosis in a Rat Model of Chronic Kidney Disease release_eyxuocuvzzhi5hye7gqnkvhzby

by Y. Matsumoto, S. Ueda, S.-i. Yamagishi, K. Matsuguma, R. Shibata, K. Fukami, H. Matsuoka, T. Imaizumi, S. Okuda

References

NOTE: currently batch computed and may include additional references sources, or be missing recent changes, compared to entity reference list.
Fuzzy reference matching is a work in progress!
Read more about quality, completeness, and caveats in the fatcat guide.
Showing 1 - 30 of 50 references (in 215ms)
[18.5.1525.1]

via crossref
Does ADMA Cause Endothelial Dysfunction?
J. P. Cooke
2000   Arteriosclerosis, Thrombosis and Vascular Biology
doi:10.1161/01.atv.20.9.2032  pmid:10978245 
web.archive.org [PDF]
[b1]

via fuzzy
Asymmetric Dimethylarginine (ADMA) and Cardiovascular Disease
Seiji Ueda, Sho-ichi Yamagishi, Utako Kaneyuki, Seiya Okuda
2008   Vascular Disease Prevention
doi:10.2174/1567270000603010041 
[18.5.1525.3]

via crossref
Asymmetrical Dimethylarginine, an Endogenous Nitric Oxide Synthase Inhibitor, in Experimental Hypertension
H. Matsuoka, S. Itoh, M. Kimoto, K. Kohno, O. Tamai, Y. Wada, H. Yasukawa, G. Iwami (+ more)
1997   Hypertension
doi:10.1161/01.hyp.29.1.242  pmid:9039109 
web.archive.org [PDF]
[18.5.1525.4]

via crossref
Endogenous Nitric Oxide Synthase Inhibitor
Hiroshi Miyazaki, Hidehiro Matsuoka, John P. Cooke, Michiaki Usui, Seiji Ueda, Seiya Okuda, Tsutomu Imaizumi
1999   Circulation
doi:10.1161/01.cir.99.9.1141  pmid:10069780 
web.archive.org [PDF]
[18.5.1525.5]

via crossref
Elevated Plasma Asymmetric Dimethylarginine as a Marker of Cardiovascular Morbidity in Early Diabetic Nephropathy in Type 1 Diabetes
L. Tarnow, P. Hovind, T. Teerlink, C. D.A. Stehouwer, H.-H. Parving
2004   Diabetes Care
doi:10.2337/diacare.27.3.765  pmid:14988299 
web.archive.org [PDF]
[18.5.1525.6]

via crossref
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
A. Leone, S. Moncada, P. Vallance, A. Calver, J. Collier
1992   The Lancet
doi:10.1016/0140-6736(92)90865-z  pmid:1347093 
[18.5.1525.7]

via crossref
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study
Carmine Zoccali, Stefanie M Bode-Böger, Francesca Mallamaci, Frank Antonio Benedetto, Giovanni Tripepi, Lorenzo Salvatore Malatino, Alessandro Cataliotti, Ignazio Bellanuova (+ more)
2001   The Lancet
doi:10.1016/s0140-6736(01)07217-8  pmid:11784625 
web.archive.org [PDF]
[18.5.1525.8]

via crossref
Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine
Veli-Pekka Valkonen, Hannu Päivä, Jukka T Salonen, Timo A Lakka, Terho Lehtimäki, Juha Laakso, Reijo Laaksonen
2001   The Lancet
doi:10.1016/s0140-6736(01)07184-7  pmid:11784629 
[18.5.1525.9]

via crossref
Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients With Coronary Artery Disease: Results from the AtheroGene Study
R. Schnabel
2005   Circulation Research
doi:10.1161/01.res.0000181286.44222.61  pmid:16100045 
web.archive.org [PDF]
[18.5.1525.10]

via crossref
Molecular Mechanism for Elevation of Asymmetric Dimethylarginine and Its Role for Hypertension in Chronic Kidney Disease
K. Matsuguma
2006   Journal of the American Society of Nephrology
doi:10.1681/asn.2005121379  pmid:16807406 
web.archive.org [PDF]
[18.5.1525.11]

via crossref
Asymmetric Dimethylarginine and Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study
D. Fliser
2005   Journal of the American Society of Nephrology
doi:10.1681/asn.2005020179  pmid:15930091 
web.archive.org [PDF]
[18.5.1525.12]

via crossref
Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney Disease: A Competing Risks Modeling Approach
P. Ravani
2005   Journal of the American Society of Nephrology
doi:10.1681/asn.2005010076  pmid:15944335 
web.archive.org [PDF]
[18.5.1525.13]

via crossref
Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?
Carmine Zoccali, Jan T Kielstein
2006   Current opinion in nephrology and hypertension
doi:10.1097/01.mnh.0000222701.22583.e8  pmid:16609301 
[18.5.1525.14]

via crossref
Nitric Oxide Modulates Vascular Disease in the Remnant Kidney Model
Duk-Hee Kang, Takahiko Nakagawa, Lili Feng, Richard J. Johnson
2002   American Journal of Pathology
doi:10.1016/s0002-9440(10)64175-2  pmcid:PMC1850677  pmid:12107108 
web.archive.org [PDF]
[18.5.1525.15]

via crossref
Protection of Wistar Furth Rats from Chronic Renal Disease Is Associated with Maintained Renal Nitric Oxide Synthase
A. Erdely
2003   Journal of the American Society of Nephrology
doi:10.1097/01.asn.0000086476.48686.7d  pmcid:PMC2747486  pmid:14514730 
web.archive.org [PDF]
[18.5.1525.16]

via crossref
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia.
T Murohara, T Asahara, M Silver, C Bauters, H Masuda, C Kalka, M Kearney, D Chen (+ more)
1998   Journal of Clinical Investigation
doi:10.1172/jci1560  pmcid:PMC508846  pmid:9616228 
web.archive.org [PDF]
[18.5.1525.17]

via crossref
Regulation of Cytokine-Induced Nitric Oxide Synthesis by Asymmetric Dimethylarginine: Role of Dimethylarginine Dimethylaminohydrolase
S. Ueda
2002   Circulation Research
doi:10.1161/01.res.0000052990.68216.ef  pmid:12574151 
web.archive.org [PDF]
[18.5.1525.18]

via crossref
Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF
Sho-ichi Yamagishi, Kazuo Nakamura, Seiji Ueda, Seiya Kato, Tsutomu Imaizumi
2005   Cell and Tissue Research
doi:10.1007/s00441-005-1094-8  pmid:15846509 
[18.5.1525.19]

via crossref
Biochemical Evidence for Impaired Nitric Oxide Synthesis in Patients With Peripheral Arterial Occlusive Disease
R. H. Boger, S. M. Bode-Boger, W. Thiele, W. Junker, K. Alexander, J. C. Frolich
1997   Circulation
doi:10.1161/01.cir.95.8.2068  pmid:9133517 
web.archive.org [PDF]
[18.5.1525.20]

via crossref
Symmetric dimethylarginine (SDMA) as endogenous marker of renal function—a meta-analysis
Jan T. Kielstein, Shelley R. Salpeter, Stefanie M. Bode-Boeger, John P. Cooke, Danilo Fliser
2006   Nephrology, Dialysis and Transplantation
doi:10.1093/ndt/gfl292  pmid:16766542 
[18.5.1525.21]

via crossref
Symmetrical Dimethylarginine: A New Combined Parameter for Renal Function and Extent of Coronary Artery Disease
S. M. Bode-Boger
2006   Journal of the American Society of Nephrology
doi:10.1681/asn.2005101119  pmid:16481412 
web.archive.org [PDF]
[18.5.1525.22]

via crossref
Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats
Katari A. Carello, Steven E. Whitesall, Mary C. Lloyd, Scott S. Billecke, Louis G. D'Alecy
2006   American Journal of Physiology. Heart and Circulatory Physiology
doi:10.1152/ajpheart.00208.2005  pmid:16113067 
web.archive.org [PDF]
[b22]

via grobid
Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ: Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12: 1448 -1457, 2001
[18.5.1525.24]

via crossref
Regression of Renal Vascular and Glomerular Fibrosis: Role of Angiotensin II Receptor Antagonism and Matrix Metalloproteinases
J.-J. Boffa
2003   Journal of the American Society of Nephrology
doi:10.1097/01.asn.0000060574.38107.3b  pmid:12707384 
web.archive.org [PDF]
[18.5.1525.25]

via crossref
TGF-β1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy
Kiyoshi Tamaki, Seiya Okuda, Takashi Ando, Taketo Iwamoto, Masaru Nakayama, Masatoshi Fujishima
1994   Kidney International
doi:10.1038/ki.1994.68  pmid:8164441 
web.archive.org [PDF]
[18.5.1525.26]

via crossref
Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix.
S Okuda, L R Languino, E Ruoslahti, W A Border
1990   Journal of Clinical Investigation
doi:10.1172/jci114731  pmcid:PMC296747  pmid:2200803 
web.archive.org [PDF]
[18.5.1525.27]

via crossref
ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease
K. Caglar, M.I. Yilmaz, A. Sonmez, E. Cakir, A. Kaya, C. Acikel, T. Eyileten, M. Yenicesu (+ more)
2006   Kidney International
doi:10.1038/sj.ki.5001632  pmid:16820789 
web.archive.org [PDF]
[18.5.1525.28]

via crossref
Marked Increase of Asymmetric Dimethylarginine in Patients with Incipient Primary Chronic Renal Disease
Jan T. Kielstein, Rainer H. Böger, Stefanie M. Bode-Böger, Jürgen C. Frölich, Hermann Haller, Eberhard Ritz, Danilo Fliser
2002   Journal of the American Society of Nephrology
doi:10.1681/asn.v131170 
web.archive.org [PDF]
[b28]

via grobid
Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Boger R; CREED Investigators: Asymmetric dimethylarginine, c-reactive protein, and carotid intima- media thickness in end-stage renal disease. J Am Soc Neph- rol 13: 490 -496, 2002
[18.5.1525.30]

via crossref
Interference ofL-Arginine Analogues withL-Arginine Transport Mediated by the y+Carrier hCAT-2B
Ellen I. Closs, Fatima Z. Basha, Alice Habermeier, Ulrich Förstermann
1997   Nitric oxide
doi:10.1006/niox.1996.0106  pmid:9701046 
Showing 1 - 30 of 50 references  next »